Page 1

VISTIN PHARMA ASA - FIRST QUARTER REPORT 2021 VISTIN PHARMA VISTIN PHARMA ASA FIRST QUARTER 2021 RESULTS PUBLISHED 23 April 2021 ■ HIGHLIGHTS Revenue of MNOK 70.8 for the quarter compared to MNOK 61.4 in first quarter 2020 ( + 15 % ) . Revenue positively affected by product mix and slightly favorable EURNOK compared to last year EBITDA of MNOK 16.3 in first quarter 2021 compared to MNOK 14.2 in first quarter 2020 ( + 15 % ) . EBITDA favorably affected by product mix and FX , partly offset by record high transportation cost and electricity prices in the quarter All time high production volume in the quarter driven by full effect of the 2nd reactor installed in Q3 / Q4'20 Metformin capacity expansion project ( MEP ) on track and expected to be commercially operational from Q2 2022. Approximately 35 % of the total investment of MNOK 100 paid as of end March . Cash balance of MNOK 85 as of 31 March and no interest - bearing debt Dividend proposal for the AGM ( 20.05.2021 ) NOK 0.5 per share for 2020 1